Cubist Stressing Cidecin Short Duration Of Therapy; NDA Has Priority Review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cubist plans to highlight a shorter duration of therapy with Cidecin (daptomycin) to differentiate the pending antibiotic from currently marketed agents for Gram-positive infections.
You may also be interested in...
Cidecin Manufacturing Issues Could Delay Launch By “A Number Of Weeks”
Manufacturing issues are likely to delay the launch of Cubist’s cyclic lipopeptide antibiotic Cidecin by “a number of weeks” after the anticipated Sept. 20 approval, the firm said.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product